Skip to main content
. Author manuscript; available in PMC: 2020 Mar 27.
Published in final edited form as: Nucl Med Biol. 2019 Dec 13;80-81:57–64. doi: 10.1016/j.nucmedbio.2019.12.004

Fig. 3.

Fig. 3

Clonogenic assay (n = 3) of HER2-positive HCC1954 cells incubated for 1 h with [67Ga]Ga-THP-trastuzumab or [111In]In-DOTA-trastuzumab at 0.18 MBq/μg over a range of concentrations (A), activity per mL during incubation (B), and activity bound per cell (C). In D, controls non-internalised activity in HER2-positive HCC1954 cells incubated ([67Ga]Ga-THP and [111In]In-DOTA; 1 MBq, 2 MBq/mL), HER2-negative MDA-MB-231 cells incubated with 100 nM radiolabelled trastuzumab, and HER2-positive HCC1954 cells incubated with 100 nM non-radiolabelled trastuzumab (n = 6).